Quince Therapeutics Says Last Patient Completed Last Visit In Pivotal Phase 3 NEAT Clinical Trial Of eDSP, In Patients With Ataxia-Telangiectasia; Expects To Report Topline Results From In Q1 2026

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company's pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022)clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patients with Ataxia-Telangiectasia (A-T). The company expects to report topline results from this study in the middle of the first quarter of 2026.